Acquired control of Nanda Pharmaceutical to achieve "human-derived protein raw material-preparation integration"

Won the Second Prize of Jiangsu Provincial Science and Technology Award in 2023

Marketing application for the new indication of Ainuomiti Tablets was approved

Selected as a National Specialized, Sophisticated, Unique and New "Little Giant" Enterprise

Marketing application for Ainuovirine API was approved, and mass production officially started

Two of the company's anti-AIDS innovative drugs were included in the Chinese Guidelines for the Diagnosis and Treatment of AIDS (2024 Edition)

Selected into the "2023 China Small Molecule Drug Enterprise Innovation Power TOP30 Ranking"

The wholly-owned subsidiary "Chengdu Aidea" grandly commenced operations

Won the title of "2023 Yangzhou Private Enterprise Innovation Top 20"

Re-certified as a "High-Tech Enterprise"